Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18056891rdf:typepubmed:Citationlld:pubmed
pubmed-article:18056891lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C0021641lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C0085536lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C1419102lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C0205734lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C1414925lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C0474643lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C0205275lld:lifeskim
pubmed-article:18056891lifeskim:mentionsumls-concept:C1518422lld:lifeskim
pubmed-article:18056891pubmed:issue3lld:pubmed
pubmed-article:18056891pubmed:dateCreated2008-2-29lld:pubmed
pubmed-article:18056891pubmed:abstractTextWe previously demonstrated the presence of two different populations among individuals with adult-onset autoimmune diabetes: those having either a high titer or a low titer of antibodies to GAD (GADAs). Protein tyrosine phosphatase nonreceptor type 22 (PTPN22) has been identified as a new susceptibility gene for type 1 diabetes and other autoimmune diseases. The aim of the present study was to evaluate whether the phenotypic heterogeneity of adult-onset autoimmune diabetes based on the GADA titer is associated with the PTPN22 C1858T polymorphism.lld:pubmed
pubmed-article:18056891pubmed:languageenglld:pubmed
pubmed-article:18056891pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056891pubmed:citationSubsetIMlld:pubmed
pubmed-article:18056891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056891pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18056891pubmed:statusMEDLINElld:pubmed
pubmed-article:18056891pubmed:monthMarlld:pubmed
pubmed-article:18056891pubmed:issn1935-5548lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:TibertiClaudi...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:PozzilliPaolo...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:SuraciConcett...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:PetroneAntoni...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:BuzzettiRaffa...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:FalorniAlbert...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:BosiEmanueleElld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:GiaccariAndre...lld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:CapizziMarcoMlld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:CossuEfisioElld:pubmed
pubmed-article:18056891pubmed:authorpubmed-author:NIRAD Study...lld:pubmed
pubmed-article:18056891pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18056891pubmed:volume31lld:pubmed
pubmed-article:18056891pubmed:ownerNLMlld:pubmed
pubmed-article:18056891pubmed:authorsCompleteYlld:pubmed
pubmed-article:18056891pubmed:pagination534-8lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:meshHeadingpubmed-meshheading:18056891...lld:pubmed
pubmed-article:18056891pubmed:year2008lld:pubmed
pubmed-article:18056891pubmed:articleTitleThe protein tyrosine phosphatase nonreceptor 22 (PTPN22) is associated with high GAD antibody titer in latent autoimmune diabetes in adults: Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3.lld:pubmed
pubmed-article:18056891pubmed:affiliationDepartment of Clinical Science, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Rome, Italy.lld:pubmed
pubmed-article:18056891pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18056891pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:26191entrezgene:pubmedpubmed-article:18056891lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18056891lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:18056891lld:entrezgene
lhgdn:association:1348lhgdn:found_inpubmed-article:18056891lld:lhgdn
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056891lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056891lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18056891lld:pubmed